JPWO2020201038A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020201038A5 JPWO2020201038A5 JP2021557778A JP2021557778A JPWO2020201038A5 JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5 JP 2021557778 A JP2021557778 A JP 2021557778A JP 2021557778 A JP2021557778 A JP 2021557778A JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5
- Authority
- JP
- Japan
- Prior art keywords
- lipocalin mutein
- lipocalin
- medicament according
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826767P | 2019-03-29 | 2019-03-29 | |
| US62/826,767 | 2019-03-29 | ||
| EP19166435 | 2019-04-01 | ||
| EP19166435.8 | 2019-04-01 | ||
| EP19175818 | 2019-05-22 | ||
| EP19175818.4 | 2019-05-22 | ||
| EP19177568.3 | 2019-05-31 | ||
| EP19177568 | 2019-05-31 | ||
| EP19211404 | 2019-11-26 | ||
| EP19211404.9 | 2019-11-26 | ||
| PCT/EP2020/058637 WO2020201038A1 (en) | 2019-03-29 | 2020-03-27 | Inhaled administration of lipocalin muteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526367A JP2022526367A (ja) | 2022-05-24 |
| JPWO2020201038A5 true JPWO2020201038A5 (hu) | 2023-04-03 |
Family
ID=70292935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557778A Withdrawn JP2022526367A (ja) | 2019-03-29 | 2020-03-27 | リポカリンムテインの吸入投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168387A1 (hu) |
| EP (1) | EP3946417A1 (hu) |
| JP (1) | JP2022526367A (hu) |
| KR (1) | KR20210146999A (hu) |
| CN (1) | CN113939307A (hu) |
| AU (1) | AU2020253034A1 (hu) |
| CA (1) | CA3127973A1 (hu) |
| WO (1) | WO2020201038A1 (hu) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022129629A1 (en) * | 2020-12-18 | 2022-06-23 | Astrazeneca Ab | Lipocalin mutein dry powder formulation for treatment of asthma |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CA2659413C (en) | 2006-08-01 | 2016-06-14 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| EP2245054B1 (en) | 2008-01-30 | 2018-11-28 | Pieris Pharmaceuticals GmbH | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| EP3660510A3 (en) | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| CN105949301B (zh) | 2010-06-08 | 2020-03-27 | 皮里斯制药有限公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
| WO2012022742A1 (en) | 2010-08-16 | 2012-02-23 | Pieris Ag | Binding proteins for hepcidin |
| JP6100694B2 (ja) | 2010-11-15 | 2017-03-22 | ピエリス ファーマシューティカルズ ゲーエムベーハー | グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質 |
| US9221885B2 (en) | 2010-12-02 | 2015-12-29 | Pieris Ag | Muteins of human lipocalin 2 with affinity for CTLA-4 |
| AU2012350654C1 (en) | 2011-12-12 | 2018-05-10 | Pieris Ag | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| DK3453400T3 (da) | 2011-12-13 | 2021-04-06 | Pieris Pharmaceuticals Gmbh | Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer |
| WO2013174783A1 (en) | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| CN105246503A (zh) | 2013-03-14 | 2016-01-13 | 第一三共株式会社 | Pcsk9的新颖结合蛋白 |
| BR112016027024A2 (pt) | 2014-05-22 | 2017-10-31 | Pieris Pharmaceuticals Gmbh | polipeptídeos de ligação específica e seus usos |
| US10526382B2 (en) | 2015-01-28 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof |
| AU2016221816B2 (en) | 2015-02-18 | 2020-07-02 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for pyoverdine and pyochelin |
| US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| EA201890198A1 (ru) | 2015-07-15 | 2018-07-31 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новые белки, специфичные в отношении lag-3 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| EP3571219A1 (en) | 2017-01-18 | 2019-11-27 | Pieris Pharmaceuticals GmbH | Lipocalin muteins with binding affinity for lag-3 |
-
2020
- 2020-03-27 EP EP20719569.4A patent/EP3946417A1/en active Pending
- 2020-03-27 KR KR1020217035440A patent/KR20210146999A/ko unknown
- 2020-03-27 CN CN202080025546.6A patent/CN113939307A/zh active Pending
- 2020-03-27 CA CA3127973A patent/CA3127973A1/en active Pending
- 2020-03-27 WO PCT/EP2020/058637 patent/WO2020201038A1/en unknown
- 2020-03-27 JP JP2021557778A patent/JP2022526367A/ja not_active Withdrawn
- 2020-03-27 AU AU2020253034A patent/AU2020253034A1/en not_active Abandoned
- 2020-03-27 US US17/599,765 patent/US20220168387A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
| US10596146B2 (en) | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders | |
| ES2745064T3 (es) | Formulación superfina de formoterol | |
| Heinemann et al. | Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery | |
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| Douafer et al. | Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases | |
| US10391078B2 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| AU2019236630A1 (en) | Mast cell stabilizers treatment for systemic disorders | |
| JP2021193091A (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| JP2023086774A (ja) | 乾燥粉末配合および使用方法 | |
| JP2017509684A5 (hu) | ||
| KR20100091970A (ko) | 파킨슨병 치료용 조성물 | |
| JPH0648958A (ja) | 吸入による非ステロイド系抗炎症剤の抗反応抗喘息活性 | |
| JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
| JP6066350B2 (ja) | エアロゾルボーラスとしてのイロプロストの投与 | |
| EP3484458A1 (en) | Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces | |
| Kaur et al. | Advanced aerosol delivery devices for potential cure of acute and chronic diseases | |
| EP4138832A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| Beck-Broichsitter et al. | Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension | |
| IT202000005026A1 (it) | Lattoferrina per uso inalatorio ad azione antivirale | |
| Yue et al. | Inhaled drug delivery: Past, present, and future | |
| WO2015014209A1 (zh) | 稳定渗透压的丙酮酸药物组成及其在健康人和肺病病人中的排毒作用 | |
| CN106667974A (zh) | 一种吸入用硫酸特布他林溶液制备方法 | |
| JPWO2020201038A5 (hu) | ||
| JP2023551989A (ja) | 生成物送達デバイス及び方法 |